BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 17848182)

  • 1. Individualized population pharmacokinetic model with limited sampling for cyclosporine monitoring after liver transplantation in clinical practice.
    Langers P; Cremers SC; den Hartigh J; Rijnbeek EM; Ringers J; Lamers CB; Hommes DW; van Hoek B
    Aliment Pharmacol Ther; 2007 Nov; 26(10):1447-54. PubMed ID: 17848182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Easy-to-use, accurate and flexible individualized Bayesian limited sampling method without fixed time points for ciclosporin monitoring after liver transplantation.
    Langers P; Cremers SC; den Hartigh J; Rijnbeek EM; Ringers J; Lamers CB; van Hoek B
    Aliment Pharmacol Ther; 2005 Mar; 21(5):549-57. PubMed ID: 15740538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flexible limited sampling model for monitoring tacrolimus in stable patients having undergone liver transplantation with samples 4 to 6 hours after dosing is superior to trough concentration.
    Langers P; Press RR; den Hartigh J; Cremers SC; Baranski AG; Lamers CB; Hommes DW; van Hoek B
    Ther Drug Monit; 2008 Aug; 30(4):456-61. PubMed ID: 18641539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decision support tool to individualize cyclosporine dose in stable, long-term heart transplant recipients receiving metabolic inhibitors: overcoming limitations of cyclosporine C2 monitoring.
    Ray JE; Keogh AM; McLachlan AJ
    J Heart Lung Transplant; 2006 Oct; 25(10):1223-9. PubMed ID: 17045935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, controlled trial of C0- Vs C2-guided therapeutic drug monitoring of cyclosporine in stable heart transplant patients.
    Mathias HC; Ozalp F; Will MB; Borland W; Payne C; Kerr M; Lockhart J; Murday AJ
    J Heart Lung Transplant; 2005 Dec; 24(12):2137-43. PubMed ID: 16364862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limited sampling strategy for cyclosporine (Neoral) area under the curve monitoring in pediatric kidney transplant recipients.
    Strong DK; Lai A; Primmett D; White CT; Lirenman DS; Carter JE; Hurley RM; Virji M; Ensom MH
    Pediatr Transplant; 2005 Oct; 9(5):566-73. PubMed ID: 16176411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching monitoring of emulsified cyclosporine from trough level to 2-hour level in stable liver transplant patients.
    Langers P; Cremers SC; den Hartigh J; Veenendaal RA; ten Hove WR; Ringers J; Lamers CB; van Hoek B
    Liver Transpl; 2004 Feb; 10(2):183-9. PubMed ID: 14762854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study of cyclosporine level at 2 hours after administration in preoperative kidney transplant recipients for prediction of postoperative optimal cyclosporine dose.
    Sukhavasharin N; Praditpornsilpa K; Avihingsanon Y; Kuoatawintu P; O-Charoen R; Kansanabuch T; Tungsanga K; Eiam-Ong S
    J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S15-20. PubMed ID: 17044449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single time point measurement by C2 or C3 is highly predictive in cyclosporine area under the curve estimation immediately after lung transplantation.
    Hangler HB; Ruttmann E; Geltner C; Bucher B; Nagiller J; Laufer G; Mueller LC
    Clin Transplant; 2008; 22(1):35-40. PubMed ID: 18217903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring C2 level predicts exposure in maintenance lung transplant patients receiving the microemulsion formulation of cyclosporine (Neoral).
    Jaksch P; Kocher A; Neuhauser P; Sarahrudi K; Seweryn J; Wisser W; Klepetko W
    J Heart Lung Transplant; 2005 Aug; 24(8):1076-80. PubMed ID: 16102443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of area under the whole blood concentration versus time curve after first intravenous cyclosporine dose in children undergoing hematopoietic stem cell transplant: limited sampling strategies.
    Sibbald C; Seto W; Taylor T; Saunders EF; Doyle J; Dupuis LL
    Ther Drug Monit; 2008 Aug; 30(4):434-8. PubMed ID: 18641547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a predictive limited sampling strategy for estimation of mycophenolic acid area under the concentration time curve in patients receiving concomitant sirolimus or cyclosporine.
    Figurski MJ; Nawrocki A; Pescovitz MD; Bouw R; Shaw LM
    Ther Drug Monit; 2008 Aug; 30(4):445-55. PubMed ID: 18641543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Achieving adequate cyclosporine exposure in liver transplant recipients: a novel strategy for monitoring and dosing using intravenous therapy.
    Lück R; Böger J; Kuse E; Klempnauer J; Nashan B
    Liver Transpl; 2004 May; 10(5):686-91. PubMed ID: 15108262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring of cyclosporine 2-hour post-dose levels in heart transplantation: improvement in clinical outcomes.
    Delgado DH; Rao V; Hamel J; Miriuka S; Cusimano RJ; Ross HJ
    J Heart Lung Transplant; 2005 Sep; 24(9):1343-6. PubMed ID: 16143255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advantages of C2 monitoring to avoid acute rejection in pediatric heart transplant recipients.
    Schubert S; Abdul-Khaliq H; Lehmkuhl HB; Hübler M; Abd El Rahman MY; Miera O; Ewert P; Weng Y; Wei H; Krüdewagen B; Hetzer R; Berger F
    J Heart Lung Transplant; 2006 Jun; 25(6):619-25. PubMed ID: 16730566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limitations of cyclosporine C2 monitoring in pediatric heart transplant recipients.
    Hmiel SP; Canter C; Shepherd R; Lassa-Claxton S; Nadler M
    Pediatr Transplant; 2007 Aug; 11(5):524-9. PubMed ID: 17631021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abbreviated AUC monitoring of cyclosporine more adequately identified patients at risk for acute rejection during induction of immunosuppressive therapy after kidney transplantation than recommended C2 concentration values.
    Troncoso P; Ortiz AM; Jara A; Vilches S
    Transplant Proc; 2009; 41(1):127-30. PubMed ID: 19249495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics and bayesian estimator of cyclosporine in pediatric renal transplant patients.
    Irtan S; Saint-Marcoux F; Rousseau A; Zhang D; Leroy V; Marquet P; Jacqz-Aigrain E
    Ther Drug Monit; 2007 Feb; 29(1):96-102. PubMed ID: 17304156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time-dependent changes in cyclosporine exposure: implications for achieving target concentrations.
    Felipe CR; Silva HT; Machado PG; Garcia R; Moreira SR; Pestana JO
    Transpl Int; 2003 Jul; 16(7):494-503. PubMed ID: 12677364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic and pharmacodynamic correlations of cyclosporine therapy in stable renal transplant patients: evaluation of long-term target C(2).
    Brunet M; Campistol JM; Millán O; Vidal E; Esforzado N; Rojo I; Jiménez O; Oppenheimer F; Corbella J; Martorell J
    Int Immunopharmacol; 2003 Jul; 3(7):987-99. PubMed ID: 12810356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.